WO2021241720A1 - 抗体含有製剤 - Google Patents
抗体含有製剤 Download PDFInfo
- Publication number
- WO2021241720A1 WO2021241720A1 PCT/JP2021/020337 JP2021020337W WO2021241720A1 WO 2021241720 A1 WO2021241720 A1 WO 2021241720A1 JP 2021020337 W JP2021020337 W JP 2021020337W WO 2021241720 A1 WO2021241720 A1 WO 2021241720A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- sequence
- antibody
- solution
- histidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Definitions
- the present invention has a heavy chain variable region comprising CDR1 having a sequence of SEQ ID NO: 1, CDR2 having a sequence of SEQ ID NO: 2, and CDR3 having a sequence of SEQ ID NO: 3, and a sequence of SEQ ID NO: 4.
- a stable formulation comprising an antibody comprising a light chain variable region comprising CDR1, CDR2 having the sequence of SEQ ID NO: 5, and CDR3 having the sequence of SEQ ID NO: 6.
- the present invention also relates to a method for stabilizing a solution containing an anti-IL-6 receptor antibody, a method for suppressing association (for example, dimerization) of the antibody, and an insoluble particle in a solution containing the antibody. It relates to a method of suppressing the generation.
- SA237 (Satralizumab) is a humanized anti-human IL-6 receptor neutralizing antibody of modified IgG2 designed to modify the amino acid sequence of the IgG1 antibody tocilizumab and prolong the half-life in plasma. Compared with tocilizumab, SA237 1) prolongs plasma half-life by pH-dependent binding to IL-6 receptor, lowering of antibody isoelectric point, and enhanced binding to FcRn under acidic conditions. 2) It has features such as reduced binding ability to Fc ⁇ receptor and reduced effector action such as ADCC / CDC by adopting IgG2 skeleton. A clinical trial of SA237 has been conducted in patients with neuromyelitis optica spectrum disease (Non-Patent Documents 1 to 6), and it is in the manufacturing and marketing approval application stage in Japan, the United States, and Europe.
- Solutions containing high concentrations of antibody cause unwanted degradation, including the formation of insoluble and / or soluble aggregates. These insoluble and soluble aggregates are likely to be formed in the liquid state by the association of antibody molecules. When the liquid product is stored for a long period of time, deamidation of asparagine residues may cause the bioactivity of the antibody molecule to be lost or reduced. The freeze and thaw cycle also causes the formation of degraded and aggregated antibody molecules.
- Patent Document 1 a stabilizing effect by using glutamic acid has been reported.
- Patent Document 2 As an effect of the surfactant added to the pharmaceutical product, it has been reported that poloxamer 188 has a better effect of suppressing oxidation of the protein solution pharmaceutical product than polysorbates (Patent Document 2).
- Patent Document 3 an example in which histidine-HCl or citric acid is used as a buffer and arginine or a saccharide (trehalose or the like) is used as a stabilizer has been reported (Patent Document 3).
- Patent Document 3 there is a need for the development of a more stable SA237-containing formulation that suppresses the formation of aggregates and / or the formation of insoluble particles for a long period of time under storage conditions.
- an object of the present disclosure is to provide a long-term stable formulation containing an anti-IL-6 receptor antibody (Satralizumab: SA237) as an active ingredient.
- the present inventors used arginine as an isotonic agent in the preparation containing the anti-IL-6 receptor antibody (satralizumab: SA237) rather than the case where the saccharide was used. It was found that a good effect of suppressing the formation of aggregates can be obtained in the case of arginine. It was also found that a better effect of suppressing aggregate formation can be obtained when aspartic acid or glutamic acid is used as the counterion species of the histidine buffer solution than when chloride ion is used. Furthermore, it was found that the production of insoluble particles was suppressed in the pharmaceutical product by adding Poloxamer 188 at a predetermined concentration to the pharmaceutical product.
- an antibody comprising a light chain variable region comprising CDR1 having the sequence of SEQ ID NO: 4, CDR2 having the sequence of SEQ ID NO: 5, and CDR3 having the sequence of SEQ ID NO: 6.
- a lyophilized formulation that is ⁇ 6.6.
- the preparation according to any one of [1] to [3], which is substantially free of saccharides.
- [5] The formulation according to any one of [1] to [4], wherein the association of an antibody is suppressed.
- Formulation. [6] The preparation according to any one of [1] to [5], wherein the dimerization of the antibody is reduced.
- [7] The preparation according to any one of [1] to [6], wherein the dimerization of the antibody is inhibited.
- [8] The preparation according to any one of [1] to [7], wherein the production of foreign substances is suppressed.
- [9] The preparation according to any one of [1] to [8], wherein the formation of insoluble particles is suppressed.
- [16] The preparation according to any one of [1] to [15], which is for subcutaneous administration.
- [17] The preparation according to any one of [1] to [16], which is stable at 2 to 8 ° C. for at least 6 months.
- [18] The proportion of aggregates at 2-8 ° C. for at least 6 months, at least 9 months, at least 12 months, at least 15 months, at least 18 months, at least 24 months, or at least 30 months.
- the preparation according to any one of [1] to [17] which is 2.0% or less, 1.4% or less, or 0.8% or less.
- a method for stabilizing a solution containing an antibody which comprises a step of adding L-aspartic acid or L-glutamic acid to the solution, wherein the antibody is: A heavy chain variable region containing CDR1 having a sequence of SEQ ID NO: 1, CDR2 having a sequence of SEQ ID NO: 2, and CDR3 having a sequence of SEQ ID NO: 3. And an antibody comprising a light chain variable region comprising CDR1 having the sequence of SEQ ID NO: 4, CDR2 having the sequence of SEQ ID NO: 5, and CDR3 having the sequence of SEQ ID NO: 6.
- a method for suppressing the association of an antibody which comprises a step of adding L-aspartic acid or L-glutamic acid to a solution containing the antibody, wherein the antibody comprises a step of adding L-aspartic acid or L-glutamic acid.
- an antibody comprising a light chain variable region comprising CDR1 having the sequence of SEQ ID NO: 4, CDR2 having the sequence of SEQ ID NO: 5, and CDR3 having the sequence of SEQ ID NO: 6.
- a method for suppressing dimerization of an antibody which comprises a step of adding L-aspartic acid or L-glutamic acid to a solution containing the antibody.
- a method for suppressing the formation of insoluble particles in a solution containing an antibody which comprises a step of adding L-aspartic acid or L-glutamic acid to the solution, wherein the antibody comprises.
- an antibody comprising a light chain variable region comprising CDR1 having the sequence of SEQ ID NO: 4, CDR2 having the sequence of SEQ ID NO: 5, and CDR3 having the sequence of SEQ ID NO: 6.
- the numerical value in the smallest digit is rounded off to the next lower digit (for example, if the minimum digit is one digit, the first decimal place). May contain numbers.
- the numerical value of 5 is intended to include a numerical value in the range of 4.5 to 5.4.
- poloxamer 188 which is a nonionic surfactant in a specific concentration range
- poloxamer 188 is a nonionic surfactant in a specific concentration range
- the present disclosure is a solution preparation containing an anti-IL-6 receptor antibody as an active ingredient, that is, histidine-aspartate buffer or histidine-glutamate buffer, Poloxamer 188, And for solution formulations containing arginine and having a pH of 5.5-6.6.
- the solution formulation of the present disclosure includes a solution formulation that is not a redissolved solution of a lyophilized formulation, and a solution of the lyophilized formulation after redissolution.
- the solution formulation of the present disclosure is a solution formulation that is not a redissolve of a lyophilized formulation.
- the present disclosure is a lyophilized preparation containing an anti-IL-6 receptor antibody as an active ingredient, which is a histidine-aspartate buffer or a histidine-glutamate buffer, Poloxamer. 188, and a lyophilized formulation containing arginine and having a pH of 5.5-6.6 after redissolving in water.
- the formulations of the present disclosure contain aspartates or glutamates of basic amino acids (eg, histidine and / or arginine) and are substantially free of chloride and acetate ions.
- the pharmaceuticals of the present disclosure are substantially free of sugars.
- the saccharides are, for example, sucrose, trehalose, meglumine, and sorbitol. "Substantially free” in relation to the pharmaceutical product of the present disclosure means that the pharmaceutical product does not contain an amount that functions as an ingredient.
- the osmotic pressure ratio of the pharmaceutical product of the present disclosure is 0.9 to 1.3 (ratio to saline solution).
- the formation of antibody aggregates is suppressed (eg, reduced or inhibited).
- the formulations of the present disclosure suppress the formation of foreign substances (eg, insoluble particles, eg, insoluble visible particles).
- the formulations of the present disclosure are for subcutaneous administration.
- the pharmaceuticals of the present disclosure are stable at 2-8 ° C. for at least 6 months.
- the formulations of the present disclosure are at 2-8 ° C. for at least 6 months, at least 9 months, at least 12 months, at least 15 months, at least 18 months, at least 24 months, or at least 30 months.
- the proportion of aggregates is 2.0% or less, 1.8% or less, 1.6% or less, 1.4% or less, 1.2% or less, 1.0% or less, 0.8% or less, 0.7% or less, 0.6% or less, or 0.5% or less.
- the formulations of the present disclosure have an aggregate ratio of 2.0% or less, 1.8% or less, 1. 6% or less, 1.4% or less, 1.2% or less, 1.0% or less, 0.9% or less, 0.8% or less, or 0.7% or less.
- the formulations of the present disclosure are at 2-8 ° C. for at least 1 month, at least 3 months, at least 6 months, at least 9 months, at least 12 months, at least 18 months, or at least 24 months.
- the proportion of insoluble particles is 25% or less, 20% or less, 15% or less, 10% or less, 7% or less, 6% or less, 5% or less, 4% or less, 3 % Or less, 2% or less, 1% or less, or 0.5% or less.
- the pharmaceutical product of the present disclosure comprises a histidine buffer as a buffer.
- the histidine is preferably L-histidine.
- histidine may be included as a salt, examples of such salts include histidine-hydrochloride, histidine-aspartate, histidine-glutamate. It will be understood by those skilled in the art that when histidine is expressed by weight (for example, mg), the weight may be the weight of histidine alone or the weight of histidine contained in a salt containing histidine. Further, in the present disclosure, the weight or concentration of histidine may be the sum of the weight or concentration of histidine alone and the weight or concentration of histidine contained in the salt containing histidine.
- the pharmaceutical product of the present disclosure comprises arginine as an isotonic agent.
- the arginine is preferably L-arginine.
- arginine may be included as a salt, examples of such salts include arginine-hydrochloride, arginine-aspartate, arginine-glutamate. It will be understood by those skilled in the art that when arginine is expressed by weight (for example, mg), the weight may be the weight of arginine alone or the weight of arginine contained in a salt containing arginine. Further, in the present disclosure, the weight or concentration of arginine may be the sum of the weight or concentration of arginine alone and the weight or concentration of arginine contained in a salt containing arginine.
- the pharmaceutical product of the present disclosure comprises aspartic acid and / or glutamic acid as counterions.
- Aspartic acid and glutamic acid are preferably L-aspartic acid and L-glutamic acid, respectively.
- aspartic acid and glutamic acid may be included as salts, examples of such salts include histidine-aspartate, arginine-aspartate, histidine-glutamate, arginine-glutamic acid. Can be mentioned.
- weight may be the weight of the amino acid alone or the weight of the amino acid contained in the salt containing the amino acid. Understood by those skilled in the art.
- the weight or concentration of aspartic acid or glutamic acid may be the sum of the weight or concentration of the amino acid alone and the weight or concentration of the amino acid contained in the salt containing the amino acid.
- the pharmaceutical product of the present disclosure further comprises Poloxamer 188 as a nonionic surfactant.
- Poloxamer 188 may be referred to as "polyoxyethylene (160) polyoxypropylene (30) glycol” in the Japanese Pharmacopoeia standard.
- the amount and concentration of the anti-IL-6 receptor antibody contained in the pharmaceutical product of the present disclosure are not particularly limited, and depending on the subject to which the anti-IL-6 receptor antibody is administered, for example, whether it is for adults, for children, for prophylaxis, or for treatment. It can be appropriately adjusted depending on the type or severity of the disease or symptom to be prevented or treated. Therefore, the molar ratio and the weight ratio of the anti-IL-6 receptor antibody contained in the pharmaceutical product of the present disclosure to other components can take various values.
- the concentration of the anti-IL-6 receptor antibody contained in the formulation of the present disclosure in solution ie, the concentration in solution formulation, the concentration of freeze-dried formulation in solution before freeze-drying, or freezing.
- the concentration of the dry preparation in the solution after redissolution is 10 to 500 mg / mL, for example, 50 to 250 mg / mL, 60 to 200 mg / mL, 100 to 200 mg / mL, 120 to 200 mg / mL, It is 180 to 200 mg / mL, for example, 60 mg / mL, 100 mg / mL, 120 mg / mL, 180 mg / mL, and 200 mg / mL.
- the concentration of the histidine buffer (eg, histidine-aspartate buffer or histidine-glutamate buffer) contained in the formulations of the present disclosure in solution is 1 to 500 mM (eg, histidine-aspartate buffer or histidine-glutamate buffer). mmol / L), for example, 10-100 mM, 10-40 mM, for example 20 mM.
- the concentrations of Poloxamer 188 contained in the formulations of the present disclosure in solution are 0.06 to 5.0 mg / mL, such as 0.1 to 2.0 mg / mL, 0.15 to 1.0 mg / mL, 0.2. ⁇ 0.5 mg / mL, for example 0.2 mg / mL, 0.5 mg / mL.
- the concentration of arginine and / or a salt thereof contained in the present disclosure in a solution state is 3 to 500 mM (mmol / L), for example, 5 to 300 mM, 10 to 200. mM, 50-150 mM, for example 50 mM, 100 mM, 150 mM.
- the pH of the pharmaceutical product of the present disclosure in solution is 5.2 to 6.9, for example 5.5 to 6.6, 5.8 to 6.2, for example 5.5, 6.0, 6.3.
- the formulations of the present disclosure are: ⁇ 10-500 mg / mL anti-IL-6 receptor antibody, 1-500 mM histidine-aspartate buffer or histidine-glutamate buffer, -A solution preparation containing 0.06-5.0 mg / mL Poloxamer 188 and-3-500 mM arginine and having a pH of 5.2-6.9.
- the solution formulations of the present disclosure are: ⁇ 50-250 mg / mL anti-IL-6 receptor antibody, 10-100 mM histidine-aspartate buffer or histidine-glutamate buffer, -Contains 0.1-2.0 mg / mL Poloxamer 188, and-Contains 5-300 mM arginine and has a pH of 5.5-6.6.
- the formulations of the present disclosure are: (I) a container (eg, vial, cartridge or syringe); and (ii) 50-250 mg of anti-IL-6 receptor antibody per 1 mL of solution in the container.
- the formulations of the present disclosure are: (I) a container (eg, vial, cartridge or syringe); and (ii) 60-200 mg of anti-IL-6 receptor antibody per 1 mL of solution in the container.
- the formulations of the present disclosure are: (I) a container (eg, vial, cartridge or syringe); and (ii) 120 mg of anti-IL-6 receptor antibody per 1 mL of solution in the container.
- the formulations of the present disclosure are: ⁇ 10-500 mg / mL anti-IL-6 receptor antibody, 1-500 mM histidine-aspartate buffer or histidine-glutamate buffer, It is a lyophilized preparation in which a solution containing 0.06 to 5.0 mg / mL Poloxamer 188 and 3 to 500 mM arginine is freeze-dried, and the pH after redissolving in water is 5.2 to 6.9. It is a lyophilized preparation.
- the lyophilized formulations of the present disclosure are: ⁇ 50-250 mg / mL anti-IL-6 receptor antibody, 10-100 mM histidine-aspartate buffer or histidine-glutamate buffer, A solution containing 0.1-2.0 mg / mL Poloxamer 188 and 5-300 mM arginine is a lyophilized composition with a pH of 5.5-6.6 after redissolving in water.
- the formulations of the present disclosure are: (I) Container (eg, vial, cartridge or syringe); and (ii) 50-250 mg of anti-IL-6 receptor antibody per container, ⁇ 0.9-52.3 mg of L-arginine, ⁇ 1.6 to 15.5 mg of L-histidine, Lyophilized composition containing 0.1-2.0 mg of Poloxamer 188, and L-aspartic acid or L-glutamic acid, lyophilized at pH 5.5-6.6 after redissolving in water. It is an injectable preparation including the preparation.
- the pharmaceutical product of the present disclosure comprises 120 mg of anti-IL-6 receptor antibody (eg, satralizumab) per syringe (1 mL). 26.1 mg L-arginine, 3.1 mg L-histidine, -Contains 0.5 mg of Poloxamer 188, and-L-aspartic acid or L-glutamic acid as a counterion, and has a pH of 5.8 to 6.2 in solution.
- anti-IL-6 receptor antibody eg, satralizumab
- the description of the numerical value is such that the numerical value in the smallest digit (for example, one digit) is rounded off to the next lower digit (for example, if the minimum digit is one digit, the
- the formulation is 120 mg (119.5-120.4 mg) of anti-IL-6 receptor antibody (eg, satralizumab) per syringe (1 mL), ⁇ 26.1 mg (26.05 to 26.14 mg) of L-arginine, ⁇ 3.1 mg (3.05 to 3.14 mg) of L-histidine, It can also be described as containing 0.5 mg (0.45-0.54 mg) of Poloxamer 188, and L-aspartic acid or L-glutamic acid as counterions.
- anti-IL-6 receptor antibody eg, satralizumab
- the present disclosure relates to an injectable formulation or kit comprising (i) a container; and (ii) a solution formulation of the present disclosure.
- the disclosure comprises (i) a container; (ii) a lyophilized formulation of the present disclosure; and (iii) optionally, water for injection to redissolve the lyophilized formulation.
- the container for the injectable formulation or kit of the present disclosure is a plastic or glass syringe, cartridge, or vial.
- the injectable formulation of the present disclosure is a plastic syringe.
- syringes are particularly suitable for use as syringes for filling tray fillers used in mass production in industrial production. More preferably, the injectable formulation of the present disclosure is a plastic syringe with a needle.
- the material of the needle cap of the injectable preparation of the present disclosure needs to be a material that can be attached to and detached from the syringe body, has elasticity, and has low water vapor permeability, and can be in close contact with the syringe body.
- Butyl rubber (IIR) and the like can be mentioned.
- the butyl rubber may be a halogenated butyl rubber such as bromobutyl rubber (BIIR) or chlorobutyl rubber (CIIR) in addition to normal butyl rubber.
- the structure of the cap especially if the above-mentioned material is formed in a tubular shape and one end is closed and the other end has an opening that can be attached by closely surrounding the outer circumference of the injection needle or the syringe body.
- the inside of the opening may be provided with a groove or a protrusion for attaching / detaching the cap.
- the cap may be attached so as to cover from the needle tip to one end of the outer cylinder which is the syringe body, or may be attached so as to cover from the needle tip to the connector portion between the injection needle and the syringe body.
- the container for the injectable formulation or kit of the present disclosure is a dual-chamber syringe (DCS) or dual-chamber cartridge (DCC) in which the lyophilized formulation and water for injection are encapsulated in a separate compartment within the container. That is, one of the two chambers is filled with the lyophilized formulation of the present disclosure and the other is filled with water for injection.
- the water for injection is water, and optionally meets the standard of "water for injection" defined by the Japanese Pharmacopoeia.
- the pharmaceutical product of the present invention contains, if necessary, a cryoprotectant, a suspending agent, a lysis aid, an tonicity agent, a preservative, an adsorption inhibitor, a diluent, an excipient, a pH adjuster, and a painlessening agent.
- a cryoprotectant e.g., a cryoprotectant, a suspending agent, a lysis aid, an tonicity agent, a preservative, an adsorption inhibitor, a diluent, an excipient, a pH adjuster, and a painlessening agent.
- a cryoprotectant e.g., a suspending agent, e.g., a lysis aid, an tonicity agent, a preservative, an adsorption inhibitor, a diluent, an excipient, a pH adjuster, and a painlessening agent.
- the present disclosure is a method for stabilizing an antibody in a preparation containing an anti-IL-6 receptor antibody (for example, a solution preparation), which comprises L-aspartic acid (as a counterion) or L-aspartic acid.
- the present invention relates to a method comprising the step of adding L-glutamic acid.
- the present disclosure is a method of suppressing antibody association (eg, dimerization) in a formulation containing an anti-IL-6 receptor antibody (eg, a solution formulation). It relates to a method comprising the step of adding L-aspartic acid or L-glutamic acid (as a counterion).
- the present disclosure is a method for suppressing the formation of foreign substances and insoluble particles in a preparation containing an anti-IL-6 receptor antibody (for example, a solution preparation), in which L-aspartic acid or L-glutamic acid (as a counterion) is added.
- a preparation containing an anti-IL-6 receptor antibody for example, a solution preparation
- L-aspartic acid or L-glutamic acid as a counterion
- the method of the present disclosure further comprises the step of adding Poloxamer 188 to a concentration of 0.1-2.0 mg / mL in solution.
- the insoluble particles are insoluble visible particles.
- the “stable antibody-containing preparation” in the present invention means that it is difficult to form an aggregate of a protein such as an antibody and / or insoluble particles in the preparation, that is, an insoluble aggregate, a soluble aggregate, or another insoluble particle in the preparation. It refers to a pharmaceutical product that is unlikely to undergo deterioration reactions such as the formation of particles.
- the "method for stabilizing a solution containing an antibody” refers to a method for preventing the formation of an aggregate and / or insoluble particles of a protein such as an antibody in the solution, and the association of the antibody. A method of suppressing antibody dimerization, a method of suppressing antibody-containing solution, and a method of suppressing the formation of insoluble particles in a solution containing the antibody are included.
- association refers to a state in which two or more components (eg, a polypeptide, such as an antibody) interact with each other, for example, in a composition (eg, an antibody-containing preparation, an antibody-containing solution), for example, a dimer. Embodying is mentioned.
- a composition eg, an antibody-containing preparation, an antibody-containing solution
- “suppressing association”, “suppressing aggregate”, “suppressing aggregate formation”, and “suppressing aggregate formation” are used interchangeably, and the composition (for example, an antibody-containing preparation) is used.
- An antibody-containing solution means to suppress the association between components (for example, a polypeptide, for example, an antibody).
- association eg, dimerization of the antibody is suppressed
- association of the antibody eg, dimerization
- Is reduced is used synonymously to mean that antibody association (eg, dimerization) during storage of the formulation in solution or frozen state is suppressed and that of the components of the formulation. It suffices if there are fewer antibody aggregates (eg, dimers) in the formulation compared to when at least one of them is not included (at a given concentration), and “association (eg, dimerization) is inhibited. Is included.
- association eg, dimerization
- association is suppressed (reduced or inhibited)
- association is at least 10%, 20%, 30%, 40. It refers to a decrease of%, 50%, 60%, 70%, 80%, 90%, 95%, or 100%.
- Aggregates include insoluble aggregates, soluble aggregates, etc., and aggregates and HMWS (High molecular weight) are synonymous.
- the main aggregate is the dimer.
- the amount of aggregate is determined by size exclusion chromatography (SEC), SDS polyacrylamide gel electrophoresis (SDS-PAGE), capillary SDS gel electrophoresis (CE-SDS), dynamic light scattering method (DLS), and light shielding type automatic. It can be measured by a microparticle measuring device (HIAC), flow imaging, ultracentrimetric analysis (AUC), etc., and in the present invention, it is preferably measured by size exclusion chromatography (SEC).
- SEC size exclusion chromatography
- the amount of aggregate is measured by the method described in the examples herein.
- foreign matter formation is suppressed means that foreign matter formation during storage of the preparation in a solution state or a frozen state is suppressed. This means that less foreign matter is produced in the pharmaceutical product as compared with the case where at least one of the components of the pharmaceutical product is not contained (at a predetermined concentration), and insoluble particles (for example, insoluble visible particles) are produced. It includes being suppressed.
- foreign matter formation is suppressed means that foreign matter formation is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%. , Or it means that it is reduced by 100%.
- Foreign substances include insoluble particles and the like, and insoluble particles include insoluble fine particles such as insoluble aggregates and insoluble visible particles.
- Insoluble particles can be measured by a known visual inspection machine (17th revised Japanese Pharmacopoeia general test method 6. formulation test method 6.06 insoluble foreign matter inspection method for injections), for example, the implementation of the present specification. It is measured by the method described in the example, but is not limited to this.
- anti-IL-6 receptor antibody The anti-IL-6 receptor antibody used in the present invention inhibits the binding of IL-6 to the IL-6 receptor by binding to the IL-6 receptor, and the biological activity of IL-6. Blocks the intracellular transmission of.
- anti-IL-6 receptor antibodies are CDR1 having a sequence of SEQ ID NO: 1 (heavy chain CDR1 of SA237), CDR2 having a sequence of SEQ ID NO: 2 (heavy chain CDR2 of SA237), and.
- Heavy chain variable region containing CDR3 having a sequence of SEQ ID NO: 3 (heavy chain CDR3 of SA237), and CDR1 having a sequence of SEQ ID NO: 4 (light chain CDR1 of SA237), CDR2 having a sequence of SEQ ID NO: 5.
- SA237 light chain CDR2 and an antibody comprising a light chain variable region comprising CDR3 having the sequence of SEQ ID NO: 6 (SA237 light chain CDR3).
- the antibody may be a full-length antibody or an antibody fragment, but is preferably an IgG type (for example, IgG1, IgG2, IgG3, IgG4) antibody.
- the antibody is preferably an antibody containing a heavy chain variable region of SEQ ID NO: 8 (heavy chain variable region of SA237) and a light chain variable region of SEQ ID NO: 7 (light chain variable region of SA237), and more preferably.
- antibody is used in the broadest sense and is a monoclonal antibody, polyclonal antibody, dimer, multimer, multispecific antibody (eg, two) as long as it exhibits the desired biological activity. It may be a heavily specific antibody), an antibody fragment, an antibody derivative and an antibody variant (Miller K et al. J Immunol. 2003, 170 (9), 4854-61). Antibodies may be mouse, human, humanized, chimeric, derived from other species, or artificially synthesized.
- Antibodies disclosed herein are any type (eg, IgG, IgE, IgM, IgD and IgA), class (eg, IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecules.
- the immunoglobulin can be of any species (eg, human, mouse or rabbit).
- the terms "antibody”, “immunoglobulin” and “immunoglobulin” are used in a broad sense with compatibility.
- Antibody fragment refers to a molecule other than the complete antibody, which comprises a portion of the complete antibody that binds to the antigen to which the complete antibody binds.
- Examples of antibody fragments are, but are not limited to, Fv, Fab, Fab', Fab'-SH, F (ab') 2 ; Diabody; Linear antibody; Single chain antibody molecule (eg, scFv). ); And includes a multispecific antibody formed from an antibody fragment.
- a recombinant antibody produced by using the gene recombination technology can be used.
- the DNA encoding it is cloned from antibody-producing cells such as hybridomas or sensitized lymphocytes that produce the antibody, incorporated into a vector, and introduced into a host (host cell) for production.
- a host host cell
- the antibody of the present invention can be produced by a method known to those skilled in the art. Specifically, the DNA encoding the target antibody is incorporated into the expression vector. At that time, it is incorporated into an expression vector so that it is expressed under the control of an expression control region, for example, an enhancer or a promoter. Next, the host cell is transformed with this expression vector to express the antibody. In that case, a combination of an appropriate host and expression vector can be used.
- the antibody of the present invention thus obtained can be isolated intracellularly or extracellularly (medium, etc.) and purified as a substantially pure and uniform antibody.
- the separation and purification of the antibody may be performed by using the separation and purification method used in the usual purification of the antibody, and is not limited in any way. For example, chromatographic column, filter, ultrafiltration, salting out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectric focusing, dialysis, recrystallization, etc. are appropriately selected. When combined, the antibody can be separated and purified.
- the method of defining CDR includes the method of Kabat et al. (Sequences of Proteins of Immunological Interest, 5th Ed (1991), Bethesda, MD), the method of Chothia et al. (Science (1986) 233, 755-758), antigen-antibody. Methods based on the contact region of (J Mol Biol (1996) 262, 732-745) are known, and any of these methods may be followed, or a combination thereof may be followed. Specifically, the CDR of each method is defined as follows.
- the pharmaceutical product of the present disclosure can be used to prevent and / or treat IL-6-related diseases or associated symptoms.
- the present disclosure is a solution preparation and freeze-drying which is a pharmaceutical composition for preventing and / or treating an IL-6-related disease, which comprises an anti-IL-6 receptor antibody as an active ingredient.
- the pharmaceutical product is an anti-IL-6 receptor antibody of 10 to 500 mg / mL (for example, 50 to 250 mg / mL), histidine-aspartate buffer or histidine of 1 to 500 mM (for example, 10 to 100 mM).
- - contains glutamate buffer, 0.06-5.0 mg / mL (eg 0.1-2.0 mg / mL) Poloxamer 188, and 3-500 mM (eg 5-300 mM) arginine, with a pH of 5.2- in solution. It relates to a pharmaceutical product (pharmaceutical composition), which is 6.9 (for example, 5.5 to 6.6).
- the preferable administration schedule of the antibody-containing preparation (pharmaceutical composition) of the present disclosure can be adjusted by appropriately extending the administration interval while observing the medical condition and the trend of the blood test value.
- the antibody-containing formulations (pharmaceutical compositions) of the present disclosure are at the same dose as the usual dose (eg, 120 mg / dose of antibody), eg, at regular dosing intervals (eg, as described in WO2016 / 136933). It is usually administered after a short-interval administration period in which it is administered at intervals shorter than (4 week intervals) (for example, at 2-week intervals).
- the administration of the antibody-containing preparation of the present invention can be administered to the patient via any suitable route.
- it is administered to a patient as a bolus or by an intravenous, intramuscular, or subcutaneous route by continuous infusion over a period of time.
- the antibody-containing formulations of the present invention are administered intravenously or subcutaneously.
- the antibody-containing formulations of the present invention are for subcutaneous administration.
- the "IL-6-related disease” in the present invention is an IL-6-related disease, for example, rheumatoid arthritis, juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, Castleman's disease, systemic erythematosus (SLE).
- IL-6-related disease for example, rheumatoid arthritis, juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, Castleman's disease, systemic erythematosus (SLE).
- the present disclosure is an anti-IL-6 receptor antibody for use in the prevention and / or treatment of IL-6 related diseases, wherein 10 to 500 mg / mL (eg, 50 to 50). 250 mg / mL) anti-IL-6 receptor antibody, 1-500 mM (eg 10-100 mM) histidine-aspartate buffer or histidine-glutamate buffer, 0.06-5.0 mg / mL (eg 0.1-100 mM) It is characterized by being used as a solution preparation containing Poloxamer 188 ( ⁇ 2.0 mg / mL) and arginine at 3 ⁇ 500 mM (eg 5 ⁇ 300 mM) and having a pH of 5.2 ⁇ 6.9 (eg 5.5 ⁇ 6.6).
- the present disclosure is an anti-IL-6 receptor antibody for use in the prevention and / or treatment of IL-6 related diseases, wherein 10 to 500 mg / mL (eg, 50 to 50). 250 mg / mL) anti-IL-6 receptor antibody, 1-500 mM (eg 10-100 mM) histidine-aspartate buffer or histidine-glutamate buffer, 0.06-5.0 mg / mL (eg 0.1-100 mM) Polyoxamer 188 ( ⁇ 2.0 mg / mL) and arginine at 3-500 mM (eg 5-300 mM), pH 5.2-6.9 (eg 5.5-6.6), lyophilized solution.
- the present invention relates to the anti-IL-6 receptor antibody, which is characterized in that it is redissolved and used.
- the present disclosure is a method of preventing and / or treating an IL-6-related disease, wherein the anti-IL-6 is 10 to 500 mg / mL (eg, 50 to 250 mg / mL).
- Receptor antibody 1-500 mM (eg 10-100 mM) histidine-aspartate buffer or histidine-glutamate buffer, 0.06-5.0 mg / mL (eg 0.1-2.0 mg / mL) Poloxamer 188,
- solution formulations containing 3 to 500 mM (eg 5 to 300 mM) of arginine and having a pH of 5.2 to 6.9 (eg 5.5 to 6.6) have or may be affected by IL-6 related diseases.
- the present disclosure is a method of preventing and / or treating an IL-6 related disease, wherein the anti-IL-6 is 10 to 500 mg / mL (eg, 50 to 250 mg / mL).
- Receptor antibody 1-500 mM (eg 10-100 mM) histidine-aspartate buffer or histidine-glutamate buffer, 0.06-5.0 mg / mL (eg 0.1-2.0 mg / mL) Poloxamer 188, And to prepare a lyophilized preparation by lyophilizing the solution containing 3 to 500 mM (eg, 5 to 300 mM) of arginine and having a pH of 5.2 to 6.9 (eg, 5.5 to 6.6); It relates to the above-mentioned method, which comprises re-dissolving to prepare a re-dissolved solution; and administering the re-dissolved solution to a subject who has or may have an IL-6-related disease.
- mM eg 10-100 mM
- histidine-aspartate buffer or histidine-glutamate buffer 0.06-5.0 mg / mL (eg 0.1-2.0 mg / mL) Poloxamer 188
- the "subject” is preferably an animal, more preferably a mammal (mouse, rat, rabbit, dog, monkey (eg, cynomolgus monkey), etc.), particularly preferably a human, and is a human. May be an adult (18 years or older) or a child (0-18 years or younger, eg, 6 months-18 years or younger).
- the present disclosure is the use of an anti-IL-6 receptor antibody in the manufacture of a pharmaceutical for the prevention and / or treatment of IL-6 related diseases, 10-500 mg / mg /. mL (eg 50-250 mg / mL) anti-IL-6 receptor antibody, 1-500 mM (eg 10-100 mM) histidine-aspartate buffer or histidine-glutamate buffer, 0.06-5.0 mg
- 10-500 mg / mg /. mL eg 50-250 mg / mL
- 1-500 mM eg 10-100 mM
- histidine-aspartate buffer or histidine-glutamate buffer 0.06-5.0 mg
- the present invention relates to the above-mentioned use.
- the present disclosure is the use of an anti-IL-6 receptor antibody in the manufacture of a pharmaceutical for the prevention and / or treatment of IL-6 related diseases, 10-500 mg / mg /.
- mL eg 50-250 mg / mL
- anti-IL-6 receptor antibody 1-500 mM (eg 10-100 mM) histidine-aspartate buffer or histidine-glutamate buffer, 0.06-5.0 mg Freeze-dry the solution containing / mL (eg 0.1-2.0 mg / mL) of Poloxamer 188 and 3-500 mM (eg 5-300 mM) of arginine and pH 5.2-6.9 (eg 5.5-6.6).
- the present invention relates to the above-mentioned use, which comprises preparing a lyophilized preparation.
- Example 1 Effect of pH and histidine buffer on the effect of suppressing increase in aggregates during the thermal harsh test and freeze-thaw test of satralysmab
- Example 1 Stability evaluation of satralysmab preparation in harsh tests
- Material Satralysmab is used. It is a humanized anti-IL-6 receptor monoclonal antibody for the indication of neuromyelitis optica, which is suggested to be involved in IL-6.
- N / A The measurement could not be performed because the chemical solution evaporated during storage.
- pH 4.5 and 5.0 showed a significant increase in aggregates compared with pH 5.5, 6.0 and 6.3.
- the L-histidine buffer solution showed a better aggregate inhibitory effect than the citric acid buffer solution.
- Example 2 Effect of L-arginine on suppressing increase in aggregates during heat harsh test and freeze-thaw test of satralizumab
- Example 1-1 Stability evaluation of satrarizumab preparation in harsh test (1)
- Material Example 1-1 The antibody described in 1 was used.
- Test sample 100 mg / mL satralizumab, 20 mmol / L L-histidine / hydrochloric acid buffer, 50 mmol / L NaCl, 100 mmol / L L-arginine, 100 mmol / L sucrose, and 100 mmol / L trehalose.
- Test sample 100 mg / mL satralizumab, 20 mmol / L L-histidine / hydrochloric acid buffer, 50 mmol / L NaCl, 100 mmol / L L-arginine, 100 mmol / L sucrose, and 100 mmol / L trehalose.
- the prepared drug solution was allowed to stand in a constant temperature bath at 40 ° C. for 2, 4 or 8 weeks, and used as a test sample.
- Test sample 100 mg / mL satralyzumab, 20 mmol / L L-histidine / hydrochloric acid buffer, 50 mmol / L NaCl, 100 mmol / L L-arginine, 100 mmol / L sucrose, and 100 mmol / L trehalose.
- the prepared drug solution was freeze-thawed (-20 ° C / room temperature, 5 cycles and 10 cycles) and used as a test sample.
- Example 3 Effect of L-aspartic acid on the accelerated test of satralizumab and the effect of suppressing the increase in aggregates during the freeze-thaw test
- Example 1-1 Stability evaluation of the satrarisumab preparation in the accelerated test (1)
- Material Example 1-1 The antibody described in 1 was used.
- the buffer solution was 20 mmol / L L-histidine / hydrochloric acid, 20 mmol / L histidine / L-aspartic acid and 20 mmol / L histidine / L-.
- a chemical solution having a pH of 6.0 was prepared by adding glutamic acid. The prepared drug solution was allowed to stand in a constant temperature bath at 25 ° C. for 2, 4 or 12 weeks, and used as a test sample.
- L-aspartic acid and L-glutamic acid showed a better effect of suppressing aggregate formation than chloride ions.
- the buffer solution was 20 mmol / L L-histidine / hydrochloric acid, 20 mmol / L histidine / L-aspartic acid and 20 mmol / L histidine / L-.
- a drug solution having a pH of 6.0 to which glutamic acid was added was prepared. The prepared drug solution was freeze-thawed (-20 ° C / room temperature, 5 cycles and 10 cycles) and used as a test sample.
- L-aspartic acid and L-glutamic acid showed a better effect of suppressing aggregate formation than chloride ions. Since L-glutamic acid is known to cause significant pain when administered subcutaneously, L-aspartic acid was considered to be preferable.
- Example 4 Effect of poloxamer 188 on suppressing foreign substance formation during recommended storage conditions of satralizumab
- a drug solution containing Polysorbate 20 and 0.5 mg / mL Poloxamer 188 was prepared and filled in glass vials by 1.5 mL each.
- Example 5 Stability test result of commercial formulation
- HMWS was 0.9% and 0.8%, respectively, showing a good aggregate inhibitory effect when stored for 6 months under accelerated conditions and 30 months under recommended storage conditions, respectively.
- the pharmaceutical product of the present invention is a highly stable pharmaceutical product that exhibits a high aggregate inhibitory effect in harsh tests, accelerated tests, freeze-thaw tests, and long-term storage tests under recommended storage conditions.
- the pharmaceutical product of the present invention is characterized in that foreign body production is suppressed for a long period of time despite containing a high concentration of antibody (satralizumab: SA237), for example, neuromyelitis optica spectrum (NMOSD) by subcutaneous administration. It is useful for the treatment of IL-6 related diseases such as.
Abstract
Description
SA237について視神経脊髄炎スペクトラム疾患の患者を対象とした臨床試験が行われ(非特許文献1~6)、日米欧3極において製造販売承認申請段階にある。
〔1〕50~250 mg/mLの
配列番号:1の配列を有するCDR1、配列番号:2の配列を有するCDR2、および配列番号:3の配列を有するCDR3を含む重鎖可変領域、
ならびに配列番号:4の配列を有するCDR1、配列番号:5の配列を有するCDR2、および配列番号:6の配列を有するCDR3を含む軽鎖可変領域を含む抗体;
10~100 mMのヒスチジン-アスパラギン酸塩緩衝液またはヒスチジン-グルタミン酸塩緩衝液;
0.1mg/mL ~ 2.0 mg/mLのPoloxamer 188;および
5 mM ~ 300 mMのアルギニン
を含み、pHは5.5~6.6である抗体溶液製剤。
〔2〕凍結乾燥製剤の再溶解液ではない溶液製剤である、〔1〕に記載の製剤。
〔3〕50~250 mg/mLの
配列番号:1の配列を有するCDR1、配列番号:2の配列を有するCDR2、および配列番号:3の配列を有するCDR3を含む重鎖可変領域、
ならびに配列番号:4の配列を有するCDR1、配列番号:5の配列を有するCDR2、および配列番号:6の配列を有するCDR3を含む軽鎖可変領域を含む抗体;
10~100 mMのヒスチジン-アスパラギン酸塩緩衝液またはヒスチジン-グルタミン酸塩緩衝液;
0.1mg/mL ~ 2.0 mg/mLのPoloxamer 188;および
5 mM ~ 300 mMのアルギニン
を含む溶液が凍結乾燥された組成物である凍結乾燥製剤であり、水で再溶解させた後のpHは5.5~6.6である、凍結乾燥製剤。
〔4〕糖類を実質的に含まない、〔1〕~〔3〕のいずれかに記載の製剤
〔5〕抗体の会合化が抑制されている、〔1〕~〔4〕のいずれかに記載の製剤。
〔6〕抗体の二量体化が低減されている、〔1〕~〔5〕のいずれかに記載の製剤。
〔7〕抗体の二量体化が阻害されている、〔1〕~〔6〕のいずれかに記載の製剤。
〔8〕異物の生成が抑制されている、〔1〕~〔7〕のいずれかに記載の製剤。
〔9〕不溶性粒子の生成が抑制されている、〔1〕~〔8〕のいずれかに記載の製剤。
〔10〕不溶性可視粒子の生成が抑制されている、〔1〕~〔9〕のいずれかに記載の製剤。
〔11〕(i)容器;ならびに
(ii)前記容器内に溶液1mL当たり
50~250 mgの、配列番号:1の配列を有するCDR1、配列番号:2の配列を有するCDR2、および配列番号:3の配列を有するCDR3を含む重鎖可変領域、ならびに配列番号:4の配列を有するCDR1、配列番号:5の配列を有するCDR2、および配列番号:6の配列を有するCDR3を含む軽鎖可変領域を含む抗体;
0.9~52.3mgのL-アルギニン;
1.6~15.5mgのL-ヒスチジン;
0.1mg ~ 2.0 mgのPoloxamer 188;および
L-アスパラギン酸又はL-グルタミン酸
を含み、pHは5.5~6.6である、抗体溶液製剤
を含む、注射用製剤。
〔12〕(i)容器;ならびに
(ii)前記容器内に溶液1mL当たり
60~200 mgの、配列番号:1の配列を有するCDR1、配列番号:2の配列を有するCDR2、および配列番号:3の配列を有するCDR3を含む重鎖可変領域、ならびに配列番号:4の配列を有するCDR1、配列番号:5の配列を有するCDR2、および配列番号:6の配列を有するCDR3を含む軽鎖可変領域を含む抗体;
8.7~26.1mgのL-アルギニン;
1.6~6.2mgのL-ヒスチジン;
0.15mg ~ 1.0 mgのPoloxamer 188;および
L-アスパラギン酸又はL-グルタミン酸
を含み、pHは5.5~6.3である、抗体溶液製剤
を含む、注射用製剤。
〔13〕(i)容器;ならびに
(ii)前記容器内に溶液1mL当たり
120 mgの、配列番号:1の配列を有するCDR1、配列番号:2の配列を有するCDR2、および配列番号:3の配列を有するCDR3を含む重鎖可変領域、ならびに配列番号:4の配列を有するCDR1、配列番号:5の配列を有するCDR2、および配列番号:6の配列を有するCDR3を含む軽鎖可変領域を含む抗体;
26.1mgのL-アルギニン;
3.1mgのL-ヒスチジン;
0.5 mgのPoloxamer 188;および
L-アスパラギン酸又はL-グルタミン酸
を含み、pHは5.8~6.2である、抗体溶液製剤
を含む、注射用製剤。
〔14〕前記抗体が、配列番号:8の重鎖可変領域及び配列番号:7の軽鎖可変領域を含む、〔1〕~〔13〕のいずれかに記載の製剤。
〔15〕前記抗体が、配列番号:10の配列を含む重鎖及び配列番号:9の配列を含む軽鎖を含む、〔1〕~〔14〕のいずれかに記載の製剤。
〔16〕皮下投与用である、〔1〕~〔15〕のいずれかに記載の製剤。
〔17〕2~8℃で少なくとも6ヶ月間安定である、〔1〕~〔16〕のいずれかに記載の製剤。
〔18〕2~8℃で少なくとも6ヶ月間、少なくとも9ヶ月間、少なくとも12ヶ月間、少なくとも15ヶ月間、少なくとも18ヶ月間、少なくとも24ヶ月間、または少なくとも30ヶ月間にわたって、会合体の割合が2.0%以下、1.4%以下、または0.8%以下である、〔1〕~〔17〕のいずれかに記載の製剤。
〔19〕抗体を含有する溶液を安定化する方法であって、該溶液にL-アスパラギン酸又はL-グルタミン酸を添加する工程を含み、該抗体が、
配列番号:1の配列を有するCDR1、配列番号:2の配列を有するCDR2、および配列番号:3の配列を有するCDR3を含む重鎖可変領域、
ならびに配列番号:4の配列を有するCDR1、配列番号:5の配列を有するCDR2、および配列番号:6の配列を有するCDR3を含む軽鎖可変領域を含む抗体である、方法。
〔20〕抗体の会合化を抑制する方法であって、該抗体を含有する溶液にL-アスパラギン酸又はL-グルタミン酸を添加する工程を含み、該抗体が、
配列番号:1の配列を有するCDR1、配列番号:2の配列を有するCDR2、および配列番号:3の配列を有するCDR3を含む重鎖可変領域、
ならびに配列番号:4の配列を有するCDR1、配列番号:5の配列を有するCDR2、および配列番号:6の配列を有するCDR3を含む軽鎖可変領域を含む抗体である、方法。
〔21〕抗体の二量体化を抑制する方法であって、該抗体を含有する溶液にL-アスパラギン酸又はL-グルタミン酸を添加する工程を含み、該抗体が、
配列番号:1の配列を有するCDR1、配列番号:2の配列を有するCDR2、および配列番号:3の配列を有するCDR3を含む重鎖可変領域、
ならびに配列番号:4の配列を有するCDR1、配列番号:5の配列を有するCDR2、および配列番号:6の配列を有するCDR3を含む軽鎖可変領域を含む抗体である、方法。
〔22〕抗体を含有する溶液における不溶性粒子の生成を抑制する方法であって、該溶液にL-アスパラギン酸又はL-グルタミン酸を添加する工程を含み、該抗体が、
配列番号:1の配列を有するCDR1、配列番号:2の配列を有するCDR2、および配列番号:3の配列を有するCDR3を含む重鎖可変領域、
ならびに配列番号:4の配列を有するCDR1、配列番号:5の配列を有するCDR2、および配列番号:6の配列を有するCDR3を含む軽鎖可変領域を含む抗体である、方法。
〔23〕溶液中の濃度が0.1mg/mL ~ 2.0 mg/mLとなるようにPoloxamer 188を添加する工程を更に含む、〔19〕~〔22〕のいずれかに記載の方法。
本発明者らは、抗IL-6受容体抗体を含有する試料の保存時の安定性を評価するために、熱加速試験(例えば、40℃での過酷試験、または25℃での加速試験)、推奨保存条件(例えば2~8℃、例えば5℃)での保存試験、および凍結融解試験により種々の添加剤の効果を検討した。その結果、緩衝剤としてヒスチジン緩衝剤を用いて抗IL-6受容体抗体含有製剤を調製することにより、クエン酸緩衝剤を用いた場合に比べ、会合体生成が抑制されることを見出した。また、製剤の溶液状態でのpHを5.5、6.0、6.3とした場合に、pHが4.5、5.0の場合よりも会合体抑制効果が高いことを見出した。さらに、等張化剤としてアルギニンを添加して抗IL-6受容体抗体含有製剤を調製することにより、糖類を用いた場合に比べて会合体生成が抑制されることを見出した。また、対イオン種としてアスパラギン酸、グルタミン酸を用いると、塩酸を用いた場合よりも会合体抑制効果が高いことを見出した。さらに、抗体含有溶液に特定の濃度範囲の非イオン性界面活性剤であるポロクサマー188を添加することによって、他の非イオン性界面活性剤(ポリソルべート80)を添加した場合に比べ、不溶性微粒子生成が抑制されることを見出した。
非限定的な別の実施態様において、本開示は、抗IL-6受容体抗体を有効成分として含有する凍結乾燥製剤であって、ヒスチジン-アスパラギン酸塩緩衝剤またはヒスチジン-グルタミン酸塩緩衝剤、Poloxamer 188、およびアルギニンを含み、水で再溶解させた後のpHが5.5~6.6である、凍結乾燥製剤に関する。
・10~500 mg/mLの抗IL-6受容体抗体、
・1~500 mMのヒスチジン-アスパラギン酸塩緩衝液またはヒスチジン-グルタミン酸塩緩衝液、
・0.06~5.0 mg/mLのPoloxamer 188、および
・3~500 mMのアルギニン
を含み、pHが5.2~6.9である、溶液製剤である。
特定の態様において、本開示の溶液製剤は、
・50~250 mg/mLの抗IL-6受容体抗体、
・10~100 mMのヒスチジン-アスパラギン酸塩緩衝液またはヒスチジン-グルタミン酸塩緩衝液、
・0.1~2.0 mg/mLのPoloxamer 188、および
・5~300 mMのアルギニン
を含み、pHが5.5~6.6である。
特定の態様において、本開示の製剤は、
(i)容器(例えば、バイアル、カートリッジまたはシリンジ);ならびに
(ii)前記容器内に溶液1mL当たり
・50~250 mgの抗IL-6受容体抗体、
・0.9~52.3mgのL-アルギニン、
・1.6~15.5mgのL-ヒスチジン、
・0.1~2.0 mgのPoloxamer 188、および
・L-アスパラギン酸又はL-グルタミン酸
を含み、pHが5.5~6.6である、抗体溶液製剤
を含む、注射用製剤である。
特定の態様において、本開示の製剤は、
(i)容器(例えば、バイアル、カートリッジまたはシリンジ);ならびに
(ii)前記容器内に溶液1mL当たり
・60~200 mgの抗IL-6受容体抗体、
・8.7~26.1mgのL-アルギニン、
・1.6~6.2mgのL-ヒスチジン、
・0.15mg ~ 1.0 mgのPoloxamer 188、および
・L-アスパラギン酸又はL-グルタミン酸
を含み、pHが5.5~6.3である、抗体溶液製剤
を含む、注射用製剤である。
特定の態様において、本開示の製剤は、
(i)容器(例えば、バイアル、カートリッジまたはシリンジ);ならびに
(ii)前記容器内に溶液1mL当たり
・120 mgの抗IL-6受容体抗体、
・26.1mgのL-アルギニン、
・3.1mgのL-ヒスチジン、
・0.5 mgのPoloxamer 188、および
・L-アスパラギン酸又はL-グルタミン酸
を含み、pHが5.8~6.2である、抗体溶液製剤
を含む、注射用製剤である。
・10~500 mg/mLの抗IL-6受容体抗体、
・1~500 mMのヒスチジン-アスパラギン酸塩緩衝液またはヒスチジン-グルタミン酸塩緩衝液、
・0.06~5.0 mg/mLのPoloxamer 188、および
・3~500 mMのアルギニン
を含む溶液が凍結乾燥された組成物である凍結乾燥製剤であり、水で再溶解させた後のpHが5.2~6.9である、凍結乾燥製剤である。
特定の態様において、本開示の凍結乾燥製剤は、
・50~250 mg/mLの抗IL-6受容体抗体、
・10~100 mMのヒスチジン-アスパラギン酸塩緩衝液またはヒスチジン-グルタミン酸塩緩衝液、
・0.1~2.0 mg/mLのPoloxamer 188、および
・5~300 mMのアルギニン
を含む溶液が凍結乾燥された組成物であり、水で再溶解させた後のpHが5.5~6.6である。
特定の態様において、本開示の製剤は、
(i)容器(例えば、バイアル、カートリッジまたはシリンジ);ならびに
(ii)前記容器当たり
・50~250 mgの抗IL-6受容体抗体、
・0.9~52.3 mgのL-アルギニン、
・1.6~15.5 mgのL-ヒスチジン、
・0.1~2.0 mgのPoloxamer 188、および
・L-アスパラギン酸又はL-グルタミン酸
を含む溶液が凍結乾燥された組成物であり、水で再溶解させた後のpHが5.5~6.6である、凍結乾燥製剤
を含む、注射用製剤である。
・120 mgの抗IL-6受容体抗体(例えばサトラリズマブ)、
・26.1 mgのL-アルギニン、
・3.1 mgのL-ヒスチジン、
・0.5 mgのPoloxamer 188、および
・対イオンとしてのL-アスパラギン酸又はL-グルタミン酸
を含み、溶液状態でのpHが5.8~6.2である。
上記態様において、数値の記載は、最小桁(例えば、1の桁)における数値は、その一つ下の桁(例えば、最小桁が1の桁である場合は、小数第1位)において、四捨五入した数値を含むことが意図される。製剤は、1シリンジ(1 mL)当たり
・120 mg(119.5~120.4 mg)の抗IL-6受容体抗体(例えばサトラリズマブ)、
・26.1 mg(26.05~26.14 mg)のL-アルギニン、
・3.1 mg(3.05~3.14 mg)のL-ヒスチジン、
・0.5 mg(0.45~0.54 mg)のPoloxamer 188、および
・対イオンとしてのL-アスパラギン酸又はL-グルタミン酸
を含む、とも表記され得る。
非限定的な一実施態様において、本開示は、(i)容器;(ii)本開示の凍結乾燥製剤;および(iii)任意で、前記凍結乾燥製剤を再溶解するための注射用水を含む、注射用製剤またはキットに関する。一態様において、本開示の注射用製剤またはキットの容器はプラスチック製又はガラス製のシリンジ、カートリッジ、またはバイアルである。好ましくは、本開示の注射用製剤はプラスチック製のシリンジである。具体的には、シクロオレフィン系樹脂、ポリエチレン樹脂、ポリプロピレン樹脂等の樹脂が挙げられ、特に好ましくはCOP(Cyclic Olefin Polymer: シクロオレフィンポリマー)、COC(Cyclic Olefin Copolymer: シクロオレフィンコポリマー)などのシクロオレフィン系樹脂である。このようなシリンジは、特に、工業生産で大量製造する際に用いられるトレイフィラー充填用のシリンジとして使用するのに適している。
より好ましくは、本開示の注射用製剤は、針付のプラスチック製のシリンジである。本開示の注射用製剤の針キャップの素材としては、注射器本体に着脱可能、且つ注射器本体に密着可能な、弾性を有し、且つ水蒸気透過性の少ない材料である必要があり、具体的にはブチルゴム(IIR)等が挙げられる。ブチルゴムは、ノルマルブチルゴムの他、ブロモブチルゴム(BIIR)やクロロブチルゴム(CIIR)等のハロゲン化ブチルゴムであってもよい。キャップの構造としては、上述の材料がチューブ状に形成されており、一端が閉鎖し他端が注入針あるいは注射器本体の外周を密着して取り囲んで取り付け可能な開口部を有していれば特に制限はない。単層、複層、その他の構造のいずれでもよい。また、開口部の内側には、キャップを脱着するための溝や突起が付されていてもよい。キャップは、針先から注射器本体である外筒の一端までを覆うように取り付けられても、あるいは、針先から注射針と注射器本体のコネクタ部分までを覆うように取り付けられてもよい。
特定の態様において、本開示の注射用製剤またはキットの容器はデュアルチャンバーシリンジ(DCS)またはデュアルチャンバーカートリッジ(DCC)であり、凍結乾燥製剤と注射用水が容器内の別の隔室に封入されている、すなわち、2つのチャンバーの一方に本開示の凍結乾燥製剤が、もう一方に注射用水が充填されている。好ましくは、注射用水は、水であり、任意で、日本薬局方に定められる「注射用水」の規格を満たす。
また、本明細書において「抗体を含有する溶液を安定化する方法」とは、当該溶液における抗体等のタンパク質の会合体及び/又は不溶性粒子の生成を起こりにくくする方法を指し、抗体の会合化を抑制する方法、抗体の二量体化を抑制する方法、および抗体を含有する溶液における不溶性粒子の生成を抑制する方法が含まれる。
本開示の抗体含有製剤(溶液製剤または凍結乾燥製剤)との関連において、抗体の「会合化(例えば二量体化)が抑制されている」と「抗体の会合化(例えば二量体化)が低減されている」は同義で用いられ、溶液状態または凍結状態における当該製剤の保存時の抗体の会合化(例えば二量体化)が抑制されていることを意味し、当該製剤の成分のうちの少なくとも1つを(所定の濃度で)含まない場合と比較して当該製剤において抗体の会合体(例えば二量体)が少なければよく、「会合化(例えば二量体化)が阻害されている」ことが含まれる。本明細書において、「会合化(例えば二量体化)が抑制(低減または阻害)されている」とは、会合化(例えば二量体化)が少なくとも10%、20%、30%、40%、50%、60%、70%、80%、90%、95%、または100%だけ減少していることを指す。
本発明で使用される抗IL-6受容体抗体は、IL-6受容体と結合することにより、IL-6のIL-6受容体への結合を阻害してIL-6の生物学的活性の細胞内への伝達を遮断する。そのような抗IL-6受容体抗体の例としては、配列番号:1の配列を有するCDR1(SA237の重鎖CDR1)、配列番号:2の配列を有するCDR2(SA237の重鎖CDR2)、および配列番号:3の配列を有するCDR3(SA237の重鎖CDR3)を含む重鎖可変領域、ならびに配列番号:4の配列を有するCDR1(SA237の軽鎖CDR1)、配列番号:5の配列を有するCDR2(SA237の軽鎖CDR2)、および配列番号:6の配列を有するCDR3(SA237の軽鎖CDR3)を含む軽鎖可変領域を含む抗体が挙げられる。当該抗体は、全長抗体であっても抗体断片であってもよいが、好ましくはIgG型(例えば、IgG1、IgG2、IgG3、IgG4)の抗体である。当該抗体は、好ましくは、配列番号:8の重鎖可変領域(SA237の重鎖可変領域)及び配列番号:7の軽鎖可変領域(SA237の軽鎖可変領域)を含む抗体であり、さらに好ましくは、配列番号:10の配列を含む重鎖(SA237の重鎖)及び配列番号:9の配列を含む軽鎖(SA237の軽鎖)を含む抗体であり、特に好ましくはSA237(サトラリズマブ)である。
CDR Kabat Chothia Contact
L1 L24-L34 L24-L34 L30-L36
L2 L50-L56 L50-L56 L46-L55
L3 L89-L97 L89-L97 L89-L96
H1 H31-H35B H26-H32/34 H30-H35B (Kabatナンバリング)
H1 H31-H35 H26-H32 H30-H35 (Chothiaナンバリング)
H2 H50-H65 H52-H56 H47-H58
H3 H95-H102 H95-H102 H93-H101
非限定的な一実施態様において、本開示の製剤は、IL-6関連疾患又はそれに伴う症状を予防及び/又は治療するために使用することができる。
非限定的な一実施態様において、本開示は、抗IL-6受容体抗体を有効成分として含む、IL-6関連疾患を予防及び/又は治療するための医薬組成物である溶液製剤および凍結乾燥製剤であって、10~500 mg/mL(例えば50~250 mg/mL)の抗IL-6受容体抗体、1~500 mM(例えば10~100 mM)のヒスチジン-アスパラギン酸塩緩衝液またはヒスチジン-グルタミン酸塩緩衝液、0.06~5.0 mg/mL(例えば0.1~2.0 mg/mL)のPoloxamer 188、および3~500 mM(例えば5~300 mM)のアルギニンを含み、溶液状態でのpHが5.2~6.9(例えば5.5~6.6)である、製剤(医薬組成物)に関する。
非限定的な一実施態様において、本開示は、IL-6関連疾患の予防及び/又は治療に使用するための抗IL-6受容体抗体であって、10~500 mg/mL(例えば50~250 mg/mL)の抗IL-6受容体抗体、1~500 mM(例えば10~100 mM)のヒスチジン-アスパラギン酸塩緩衝液またはヒスチジン-グルタミン酸塩緩衝液、0.06~5.0 mg/mL(例えば0.1~2.0 mg/mL)のPoloxamer 188、および3~500 mM(例えば5~300 mM)のアルギニンを含み、pHが5.2~6.9(例えば5.5~6.6)である、溶液が凍結乾燥された凍結乾燥製剤を再溶解して使用することを特徴とする、前記抗IL-6受容体抗体に関する。
非限定的な一実施態様において、本開示は、IL-6関連疾患を予防及び/又は治療する方法であって、10~500 mg/mL(例えば50~250 mg/mL)の抗IL-6受容体抗体、1~500 mM(例えば10~100 mM)のヒスチジン-アスパラギン酸塩緩衝液またはヒスチジン-グルタミン酸塩緩衝液、0.06~5.0 mg/mL(例えば0.1~2.0 mg/mL)のPoloxamer 188、および3~500 mM(例えば5~300 mM)のアルギニンを含み、pHが5.2~6.9(例えば5.5~6.6)である、溶液を凍結乾燥させて凍結乾燥製剤を調製すること;前記凍結乾燥製剤を再溶解させて再溶解液を調製すること;ならびに前記再溶解液を、IL-6関連疾患に罹患した又は罹患している恐れのある対象に投与すること、を含む前記方法に関する。
非限定的な一実施態様において、本開示は、IL-6関連疾患の予防及び/又は治療のための医薬の製造における、抗IL-6受容体抗体の使用であって、10~500 mg/mL(例えば50~250 mg/mL)の抗IL-6受容体抗体、1~500 mM(例えば10~100 mM)のヒスチジン-アスパラギン酸塩緩衝液またはヒスチジン-グルタミン酸塩緩衝液、0.06~5.0 mg/mL(例えば0.1~2.0 mg/mL)のPoloxamer 188、および3~500 mM(例えば5~300 mM)のアルギニンを含み、pHが5.2~6.9(例えば5.5~6.6)である、溶液を凍結乾燥させて凍結乾燥製剤を調製することを特徴とする、前記使用に関する。
本発明は、以下の実施例によってさらに例示されるが、下記の実施例に限定されるものではない。
〔1-1〕サトラリズマブ製剤の過酷試験での安定性評価
(1)材料
サトラリズマブは、IL-6の関与が示唆される視神経脊髄炎などを適応疾患とするヒト化抗IL-6受容体モノクローナル抗体である。
100 mg/mL サトラリズマブ、150 mmol/L NaClに対し、20 mmol/L L-ヒスチジン緩衝液及び20 mmol/L クエン酸緩衝液をそれぞれpH4.5、5.0、5.5、6.0及び6.3に調製した緩衝液を調製した。調製した薬液を40℃の恒温槽内に2、4、8週間静置したものを、被験試料とした。
試料は、カラム(東ソー、TSK Gel G3000SWxL)を用い、50 mmol/Lリン酸緩衝液(pH 7.0)、300 mmol/L塩化カリウムを移動相に用い、流速0.5 mL/minで行ったサイズ排除クロマトグラフィー(SEC)により会合体量を測定した。
検出されるピークの内,面積,高さ共に最大のものをモノマー体,モノマー体の前に検出されるピークの総称を会合体(HMWS)とした。
すべてのピークについて面積を算出し、以下の式に従って対象ピークのピーク面積比率を算出した。
得られた結果を表1に示す。
(1)材料
実施例1-1に記載した抗体を使用した。
100 mg/mL サトラリズマブ、150 mmol/L NaClに対し、20 mmol/L L-ヒスチジン緩衝液及び20 mmol/L クエン酸緩衝液をそれぞれpH4.5、5.0、5.5、6.0及び6.3に調製した緩衝液を調製した。調製した薬液を凍結融解(-20℃/室温、5サイクル及び10サイクル)したものを、被験試料とした。
(3)サトラリズマブの会合体量測定方法
実施例1-1に記載した方法に従った。
得られた結果を表 2に示す。
〔2-1〕サトラリズマブ製剤の過酷試験での安定性評価
(1)材料
実施例1-1に記載した抗体を使用した。
100 mg/mL サトラリズマブ、20mmol/L L-ヒスチジン/塩酸緩衝液、50 mmol/L NaClに対し、100 mmol/L L-アルギニン、100 mmol/L スクロース、及び100 mmol/L トレハロースを添加したpH 6.5の薬液を調製した。調製した薬液を40℃の恒温槽内に2、4、8週間静置したものを、被験試料とした。
試料は、カラム(東ソー、TSK Gel G3000SWxL)を用い、50 mmol/Lリン酸緩衝液(pH 7.0)、300 mmol/L塩化ナトリウムを移動相に用い、流速0.5 mL/minで行ったサイズ排除クロマトグラフィー(SEC)により会合体量を測定した。
検出されるピークの内,面積,高さ共に最大のものをモノマー体,モノマー体の前に検出されるピークの総称を会合体(HMWS)とした。
すべてのピークについて面積を算出し、以下の式に従って対象ピークのピーク面積比率を算出した。
得られた結果を表3に示す。
(1)材料
実施例1-1に記載した抗体を使用した。
100 mg/mL サトラリズマブ、20mmol/L L-ヒスチジン/塩酸緩衝液、50 mmol/L NaClに対し、100 mmol/L L-アルギニン、100 mmol/L スクロース、及び100 mmol/L トレハロースを添加したpH 6.5の薬液を調製した。調製した薬液を凍結融解(-20℃/室温、5サイクル及び10サイクル)したものを、被験試料とした。
実施例2-1に記載した方法に従った。
得られた結果を表4に示す。
(1)材料
実施例1-1に記載した抗体を使用した。
200 mg/mL サトラリズマブ、20 mmol/L L-ヒスチジン/塩酸緩衝液に対し、L-アルギニン濃度が50mmol/L、100 mmol/L及び150 mmol/Lになるように調整したpH6.0の薬液を調製した。調製した薬液を40℃の恒温槽内に2、4、8週間静置したもの、5℃の恒温槽内に3、6、12、18、24カ月静置したものを、被験試料とした。
実施例1-1に記載した方法に従った。
得られた結果を表5、6に示す。
(1)材料
実施例1-1に記載した抗体を使用した。
200 mg/mL サトラリズマブ、20 mmol/L L-ヒスチジン/塩酸緩衝液に対し、L-アルギニン濃度が50mmol/L、100 mmol/L及び150 mmol/Lになるように薬液を調製した。調製したpH6.0の薬液を凍結融解(-20℃/室温、5サイクル及び10サイクル)したものを、被験試料とした。
実施例2-1に記載した方法に従った。
得られた結果を表7に示す。
〔3-1〕サトラリズマブ製剤の加速試験での安定性評価
(1)材料
実施例1-1に記載した抗体を使用した。
200 mg/mL サトラリズマブ及び50mmol/Lアルギニンに対し、緩衝液が20 mmol/L L-ヒスチジン/塩酸、20 mmol/L ヒスチジン/L-アスパラギン酸及び20 mmol/L ヒスチジン/L-グルタミン酸を添加したpH6.0の薬液を調製した。調製した薬液を25℃の恒温槽内に2、4、12週間静置したものを、被験試料とした。
実施例2-1に記載した方法に従った。
得られた結果を表8に示す。
(1)材料
実施例1-1に記載した抗体を使用した。
200 mg/mL サトラリズマブ及び50mmol/Lアルギニンに対し、緩衝液が20 mmol/L L-ヒスチジン/塩酸、20 mmol/L ヒスチジン/L-アスパラギン酸及び20 mmol/L ヒスチジン/L-グルタミン酸を添加したpH6.0の薬液を調製した。調製した薬液を凍結融解(-20℃/室温、5サイクル及び10サイクル)したものを、被験試料とした。
実施例2-1に記載した方法に従った。
得られた結果を表9に示す。
〔4-1〕サトラリズマブ製剤の推奨保存試験での安定性評価
(1)材料
実施例1-1に記載した抗体を使用した。
180 mg/mL サトラリズマブ、20 mmol/L L-ヒスチジン/L-アスパラギン酸緩衝液、150mmol/L L-アルギニン、pH6.0の薬液に対し、界面活性剤として0.05mg/mL ポリソルべート80(Polysorbate 20)及び0.5 mg/mLポロクサマー188(Poloxamer 188)を添加した薬液を調製し、ガラスバイアルに1.5 mLずつ充填した。充てんした薬液を5℃の恒温槽内に1、3、6、9、12、18、24カ月静置したものを、被験試料とした。
試料は、目視検査機(Eisai社 APK03)を用いて、試料液面がバイアル底に到達するまで回転させた。回転を停止させ1試料当たり15秒間目視検査をし、不溶性可視粒子の有無を確認した。
得られた結果を表10に示す。
(1)材料
実施例1-1に記載した抗体を使用した。
180 mg/mL サトラリズマブ、20 mmol/L L-ヒスチジン/L-アスパラギン酸緩衝液、150mmol/L L-アルギニン、pH6.0の薬液に対し、0.1mg/mLになるようにシリコーン油を添加した後、界面活性剤としてポロクサマー188 が0.005mg/mL、0.055mg/mL、0.205mg/mL及び0.505mg/mLになるように調製した薬液を、10mL バイアルに3mLずつ充填した。充てんした薬液を5℃の恒温槽内に3日、1、2、4、8週間静置したものを、被験試料とした。
実施例4-1に記載した方法に従った。
得られた結果を表11に示す。
〔5-1〕サトラリズマブ製剤の推奨条件及び加速条件での安定性評価
(1)材料
実施例1-1に記載した抗体を使用した。
120 mg/mL サトラリズマブ、20 mmol/L L-ヒスチジン/L-アスパラギン酸緩衝液、150mmol/L L-アルギニン、0.5 mg/mL ポロクサマー188、pH6.0に調製した薬液を25℃の恒温槽内に1、3、6か月静置したもの及び2~8℃の恒温槽内に3、6、9、12、15、18、24、30カ月静置したものを、被験試料とした。
試料は、カラム(東ソー、TSK Gel G3000SWxL)を用い、pH 7.0のリン酸緩衝液を移動相に用い、流速0.5 mL/minで行ったサイズ排除クロマトグラフィー(SEC)により会合体量を測定した。
検出されるピークの内,面積,高さ共に最大のものをモノマー体,モノマー体の前に検出されるピークの総称を会合体(HMWS)とした。
すべてのピークについて面積を算出し、以下の式に従って対象ピークのピーク面積比率を算出した。
得られた結果を表12に示す。
Claims (15)
- 50~250 mg/mLの
配列番号:1の配列を有するCDR1、配列番号:2の配列を有するCDR2、および配列番号:3の配列を有するCDR3を含む重鎖可変領域、
ならびに配列番号:4の配列を有するCDR1、配列番号:5の配列を有するCDR2、および配列番号:6の配列を有するCDR3を含む軽鎖可変領域を含む抗体;
10~100 mMのヒスチジン-アスパラギン酸塩緩衝液またはヒスチジン-グルタミン酸塩緩衝液;
0.1mg/mL ~ 2.0 mg/mLのPoloxamer 188;および
5 mM ~ 300 mMのアルギニン
を含み、pHは5.5~6.6である抗体溶液製剤。 - 凍結乾燥製剤の再溶解液ではない溶液製剤である、請求項1に記載の製剤。
- 50~250 mg/mLの
配列番号:1の配列を有するCDR1、配列番号:2の配列を有するCDR2、および配列番号:3の配列を有するCDR3を含む重鎖可変領域、
ならびに配列番号:4の配列を有するCDR1、配列番号:5の配列を有するCDR2、および配列番号:6の配列を有するCDR3を含む軽鎖可変領域を含む抗体;
10~100 mMのヒスチジン-アスパラギン酸塩緩衝液またはヒスチジン-グルタミン酸塩緩衝液;
0.1mg/mL ~ 2.0 mg/mLのPoloxamer 188;および
5 mM ~ 300 mMのアルギニン
を含む溶液が凍結乾燥された組成物である凍結乾燥製剤であり、水で再溶解させた後のpHは5.5~6.6である、凍結乾燥製剤。 - 糖類を実質的に含まない、請求項1~3のいずれか一項記載の製剤
- 抗体の会合化が抑制されている、請求項1~4のいずれか一項記載の製剤。
- (i)容器;ならびに
(ii)前記容器内に溶液1mL当たり
50~250 mgの、配列番号:1の配列を有するCDR1、配列番号:2の配列を有するCDR2、および配列番号:3の配列を有するCDR3を含む重鎖可変領域、ならびに配列番号:4の配列を有するCDR1、配列番号:5の配列を有するCDR2、および配列番号:6の配列を有するCDR3を含む軽鎖可変領域を含む抗体;
0.9~52.3mgのL-アルギニン;
1.6~15.5mgのL-ヒスチジン;
0.1mg ~ 2.0 mgのPoloxamer 188;および
L-アスパラギン酸又はL-グルタミン酸
を含み、pHは5.5~6.6である、抗体溶液製剤
を含む、注射用製剤。 - (i)容器;ならびに
(ii)前記容器内に溶液1mL当たり
60~200 mgの、配列番号:1の配列を有するCDR1、配列番号:2の配列を有するCDR2、および配列番号:3の配列を有するCDR3を含む重鎖可変領域、ならびに配列番号:4の配列を有するCDR1、配列番号:5の配列を有するCDR2、および配列番号:6の配列を有するCDR3を含む軽鎖可変領域を含む抗体;
8.7~26.1mgのL-アルギニン;
1.6~6.2mgのL-ヒスチジン;
0.15mg ~ 1.0 mgのPoloxamer 188;および
L-アスパラギン酸又はL-グルタミン酸
を含み、pHは5.5~6.3である、抗体溶液製剤
を含む、注射用製剤。 - (i)容器;ならびに
(ii)前記容器内に溶液1mL当たり
120 mgの、配列番号:1の配列を有するCDR1、配列番号:2の配列を有するCDR2、および配列番号:3の配列を有するCDR3を含む重鎖可変領域、ならびに配列番号:4の配列を有するCDR1、配列番号:5の配列を有するCDR2、および配列番号:6の配列を有するCDR3を含む軽鎖可変領域を含む抗体;
26.1mgのL-アルギニン;
3.1mgのL-ヒスチジン;
0.5 mgのPoloxamer 188;および
L-アスパラギン酸又はL-グルタミン酸
を含み、pHは5.8~6.2である、抗体溶液製剤
を含む、注射用製剤。 - 前記抗体が、配列番号:10の配列を含む重鎖及び配列番号:9の配列を含む軽鎖を含む、請求項1~8のいずれか一項記載の製剤。
- 皮下投与用である、請求項1~9のいずれか一項記載の製剤。
- 2~8℃で少なくとも6ヶ月間安定である、請求項1~10のいずれかに記載の製剤。
- 2~8℃で少なくとも6ヶ月間、少なくとも9ヶ月間、少なくとも12ヶ月間、少なくとも15ヶ月間、少なくとも18ヶ月間、少なくとも24ヶ月間、または少なくとも30ヶ月間にわたって、会合体の割合が2.0%以下、1.4%以下、または0.8%以下である、請求項1~10のいずれかに記載の製剤。
- 抗体を含有する溶液を安定化する方法であって、該溶液にL-アスパラギン酸又はL-グルタミン酸を添加する工程を含み、該抗体が、
配列番号:1の配列を有するCDR1、配列番号:2の配列を有するCDR2、および配列番号:3の配列を有するCDR3を含む重鎖可変領域、
ならびに配列番号:4の配列を有するCDR1、配列番号:5の配列を有するCDR2、および配列番号:6の配列を有するCDR3を含む軽鎖可変領域を含む抗体である、方法。 - 抗体の会合化を抑制する方法であって、該抗体を含有する溶液にL-アスパラギン酸又はL-グルタミン酸を添加する工程を含み、該抗体が、
配列番号:1の配列を有するCDR1、配列番号:2の配列を有するCDR2、および配列番号:3の配列を有するCDR3を含む重鎖可変領域、
ならびに配列番号:4の配列を有するCDR1、配列番号:5の配列を有するCDR2、および配列番号:6の配列を有するCDR3を含む軽鎖可変領域を含む抗体である方法。 - 溶液中の濃度が0.1mg/mL ~ 2.0 mg/mLとなるようにPoloxamer 188を添加する工程を更に含む、請求項13または14に記載の方法。
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL298551A IL298551A (en) | 2020-05-29 | 2021-05-28 | A formulation containing antibodies |
MX2022014650A MX2022014650A (es) | 2020-05-29 | 2021-05-28 | Formulacion que contiene anticuerpo. |
BR112022019477A BR112022019477A2 (pt) | 2020-05-29 | 2021-05-28 | Formulação que contém anticorpo |
CN202180037198.9A CN115697404A (zh) | 2020-05-29 | 2021-05-28 | 含有抗体的制剂 |
US17/926,313 US20230210991A1 (en) | 2020-05-29 | 2021-05-28 | Antibody-containing formulation |
AU2021278562A AU2021278562A1 (en) | 2020-05-29 | 2021-05-28 | Antibody-containing formulation |
CA3177698A CA3177698A1 (en) | 2020-05-29 | 2021-05-28 | Antibody-containing formulation |
EP21813767.7A EP4159236A1 (en) | 2020-05-29 | 2021-05-28 | Antibody-containing formulation |
KR1020227043601A KR20230017222A (ko) | 2020-05-29 | 2021-05-28 | 항체 함유 제제 |
JP2022526657A JP7466640B2 (ja) | 2020-05-29 | 2021-05-28 | 抗体含有製剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020-094716 | 2020-05-29 | ||
JP2020094716 | 2020-05-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021241720A1 true WO2021241720A1 (ja) | 2021-12-02 |
Family
ID=78744811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/020337 WO2021241720A1 (ja) | 2020-05-29 | 2021-05-28 | 抗体含有製剤 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230210991A1 (ja) |
EP (1) | EP4159236A1 (ja) |
JP (1) | JP7466640B2 (ja) |
KR (1) | KR20230017222A (ja) |
CN (1) | CN115697404A (ja) |
AU (1) | AU2021278562A1 (ja) |
BR (1) | BR112022019477A2 (ja) |
CA (1) | CA3177698A1 (ja) |
IL (1) | IL298551A (ja) |
MX (1) | MX2022014650A (ja) |
TW (1) | TW202210100A (ja) |
WO (1) | WO2021241720A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023100975A1 (ja) * | 2021-12-01 | 2023-06-08 | 中外製薬株式会社 | 抗体含有製剤の調製方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011090088A1 (ja) * | 2010-01-20 | 2011-07-28 | 中外製薬株式会社 | 安定化抗体含有溶液製剤 |
WO2016136933A1 (ja) | 2015-02-27 | 2016-09-01 | 中外製薬株式会社 | Il-6関連疾患治療用組成物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004075913A1 (ja) | 2003-02-28 | 2004-09-10 | Chugai Seiyaku Kabushiki Kaisha | タンパク質含有安定化製剤 |
WO2010106812A1 (en) | 2009-03-19 | 2010-09-23 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical formulation containing improved antibody molecules |
-
2021
- 2021-05-28 US US17/926,313 patent/US20230210991A1/en active Pending
- 2021-05-28 CN CN202180037198.9A patent/CN115697404A/zh active Pending
- 2021-05-28 IL IL298551A patent/IL298551A/en unknown
- 2021-05-28 EP EP21813767.7A patent/EP4159236A1/en active Pending
- 2021-05-28 BR BR112022019477A patent/BR112022019477A2/pt unknown
- 2021-05-28 KR KR1020227043601A patent/KR20230017222A/ko unknown
- 2021-05-28 JP JP2022526657A patent/JP7466640B2/ja active Active
- 2021-05-28 CA CA3177698A patent/CA3177698A1/en active Pending
- 2021-05-28 MX MX2022014650A patent/MX2022014650A/es unknown
- 2021-05-28 TW TW110119429A patent/TW202210100A/zh unknown
- 2021-05-28 AU AU2021278562A patent/AU2021278562A1/en active Pending
- 2021-05-28 WO PCT/JP2021/020337 patent/WO2021241720A1/ja unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011090088A1 (ja) * | 2010-01-20 | 2011-07-28 | 中外製薬株式会社 | 安定化抗体含有溶液製剤 |
WO2016136933A1 (ja) | 2015-02-27 | 2016-09-01 | 中外製薬株式会社 | Il-6関連疾患治療用組成物 |
Non-Patent Citations (4)
Title |
---|
CHOTHIA ET AL., SCIENCE, vol. 233, 1986, pages 755 - 758 |
J MOL BIOL, vol. 262, 1996, pages 732 - 745 |
KABAT: "Sequences of Proteins of Immunological Interest", 1991 |
MILLER K ET AL., J IMMUNOL., vol. 170, no. 9, 2003, pages 4854 - 61 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023100975A1 (ja) * | 2021-12-01 | 2023-06-08 | 中外製薬株式会社 | 抗体含有製剤の調製方法 |
JP7367262B1 (ja) | 2021-12-01 | 2023-10-23 | 中外製薬株式会社 | 抗体含有製剤の調製方法 |
Also Published As
Publication number | Publication date |
---|---|
US20230210991A1 (en) | 2023-07-06 |
JPWO2021241720A1 (ja) | 2021-12-02 |
AU2021278562A1 (en) | 2022-12-01 |
EP4159236A1 (en) | 2023-04-05 |
CN115697404A (zh) | 2023-02-03 |
TW202210100A (zh) | 2022-03-16 |
BR112022019477A2 (pt) | 2023-01-24 |
CA3177698A1 (en) | 2021-12-02 |
IL298551A (en) | 2023-01-01 |
JP7466640B2 (ja) | 2024-04-12 |
KR20230017222A (ko) | 2023-02-03 |
MX2022014650A (es) | 2022-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11612659B2 (en) | Anti-CD40 antibody formulation delivery device | |
US10899841B2 (en) | Anti-BAFFR antibody formulations and methods of use thereof | |
AU2020201249B2 (en) | Stable liquid pharmaceutical preparation | |
JP5767340B2 (ja) | 生物薬剤を含む医薬製剤 | |
CA2600588A1 (en) | Anti-madcam antibody compositions | |
JP6769879B2 (ja) | Gm−csf中和化合物を含む液体製剤 | |
CN113453719A (zh) | 包含抗cd47抗体的制剂及其制备方法和用途 | |
RU2754760C2 (ru) | Водная фармацевтическая композиция анти-il17a антитела и ее применение | |
JP7466640B2 (ja) | 抗体含有製剤 | |
JPWO2008029908A1 (ja) | 抗体を含有する安定な凍結乾燥医薬製剤 | |
EP4151233A1 (en) | Preparation comprising anti-il-23p19 antibody, preparation method therefor and use thereof | |
JP6820823B2 (ja) | 安定なIgG4に基づく結合剤の製剤 | |
WO2024006665A1 (en) | Antibody formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21813767 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022526657 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022019477 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 3177698 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021278562 Country of ref document: AU Date of ref document: 20210528 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112022019477 Country of ref document: BR Free format text: REAPRESENTE O RELATORIO DESCRITIVO COM A PAGINA 44 CORRIGIDA. |
|
ENP | Entry into the national phase |
Ref document number: 20227043601 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021813767 Country of ref document: EP Effective date: 20230102 |
|
ENP | Entry into the national phase |
Ref document number: 112022019477 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220927 |